Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Liposomal Drug Delivery in Cancer : Hematological Malignancies and Beyond

Autor: Deshantri, Anil Kumar

In the present work, liposomes loaded with glucocorticoids or proteasome inhibitors were studied in two clinically more relevant mouse tumor models: A spontaneous MMTV/neu mouse model of breast cancer. In this model, mouse mammary tumor virus (MMTV)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::fc5d5ae415407a2935ec30821c7386e1
https://dspace.library.uu.nl/handle/1874/380423

Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2.

Autor: Pastoors D; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Havermans M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Mulet-Lazaro R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Brian D; Stem Cell Group, UCL Cancer Institute, University College London, London, UK., Noort W; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer biology and immunology, Amsterdam, Netherlands., Grasel J; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany.; Division of Experimental Hematology, German Cancer Research Center, DKFZ69120 Heidelberg, Germany., Hoogenboezem R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Smeenk L; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Demmers JAA; Proteomics Center, Erasmus MC, Rotterdam, Netherlands., Milsom MD; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany.; Division of Experimental Hematology, German Cancer Research Center, DKFZ69120 Heidelberg, Germany., Enver T; Stem Cell Group, UCL Cancer Institute, University College London, London, UK., Groen RWJ; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer biology and immunology, Amsterdam, Netherlands., Bindels E; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Delwel R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands.

Publikováno v: Science advances [Sci Adv] 2024 May 17; Vol. 10 (20), pp. eadk9076. Date of Electronic Publication: 2024 May 15.

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.

Autor: de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Shirasaki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Downey-Kopyscinski SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Matthews GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Barwick BG; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Gupta VA; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Dupéré-Richer D; University of Florida Health Cancer Center, Gainesville, FL, USA., Yamano S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Hu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sheffer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Gandolfi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Ishiguro K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Meyers RM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Bryan JG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dharia NV; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hengeveld PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Brüggenthies JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Glassner BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ott CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Kwiatkowski NP; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Levy J; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA., Groen RWJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Gray NS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Culhane AC; Department of Data Sciences, Dana-Farber Cancer Institute & Harvard School of Public Health, Boston, MA, USA.; Limerick Digital Cancer Research Center, Health Research Institute, School of Medicine, University of Limerick, Limerick, Ireland., McFarland JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dempster JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Vazquez F; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. vazquez@broadinstitute.org., Tsherniak A; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. aviad@broadinstitute.org., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Ludwig Center at Harvard, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.

Publikováno v: Nature cancer [Nat Cancer] 2023 May; Vol. 4 (5), pp. 754-773. Date of Electronic Publication: 2023 May 26.

Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.

Autor: Holthof LC; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van der Schans JJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Katsarou A; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Poels R; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Gelderloos AT; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Drent E; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van Hal-van Veen SE; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Li F; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Zweegman S; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Themeli M; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Groen RWJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Mutis T; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands. t.mutis@amsterdamumc.nl.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 01; Vol. 27 (13), pp. 3793-3803. Date of Electronic Publication: 2021 Apr 21.